Can pet imaging facilitate optimization of cancer therapies?

Current Pharmaceutical Design

Volumn 18, Issue 18, 2012, Pages 2657-2669

  Kramer Marek, Gabriela ^a   Capala, Jacek ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Molecular imaging; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; BROMINE 76; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE C 11; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IODINE 124; METHIONINE C 11; OCTREOTIDE; OXYGEN 15; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN RECEPTOR; TRASTUZUMAB; VASCULOTROPIN; VITRONECTIN RECEPTOR; YTTRIUM 86;

ARTICLE; BONE SCINTISCANNING; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG HALF LIFE; ECHOGRAPHY; GLUCOSE METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHOSPHORYLATION; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 84862576530     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800492813     Document Type: Article

References (123)

1. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7: 591-607.
2. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med 2007; 13: 287-97.
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
4. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009; 35: 309-21.
5. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119: 381-7.
6. Laudadio J, Quigley DI, Tubbs R, Wolff DJ. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn 2007; 7: 53-64.
7. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 2007; 13: 183-191.
8. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83: 349-53.
9. Zaidi H, Prasad R. Advances in multimodality molecular imaging. J Med Phys 2009; 34: 122-8.
10. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-93.
11. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007; 12: 1379-89.
12. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
13. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of F-18-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
14. Picchio M, Messa C, Landoni, et al. Value of [11C] cholinepositron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.
15. Sean L Kitson VC, Andrea Ciarmiello, Diana Salvo and Luigi Mansi. Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology. Curr Radiopharm 2009; 2: 224-253.
16. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006; 36: 51-72.
17. Bouchelouche K, Capala J. 'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol 2010; 22: 274-80.
18. Huo L, Wu Z, Zhuang H, Fu Z, Dang Y. Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med 2009; 34: 874-7.
19. Ho CL, Chen S, Ho KM, Ng WK, Leung YL, Cheng TK. 11Cacetate PET/CT in multicentric angiomyolipoma of the kidney. Clin Nucl Med 2011; 36: 407-8.
20. Shibata H, Nomori H, Uno K, et al. 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med 2009; 23: 609-16.
21. Yamamoto Y, Nishiyama Y, Kimura N, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol 2008; 10: 281-7.
22. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 541-51.
23. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensitymodulated radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 1171-82.
24. Michalski MH, Chen X. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging 2011; 38: 358-77.
25. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-45.
26. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005; 32: 525-33.
27. Tai YF, Piccini P. Applications of positron emission tomography (PET) in neurology. J Neurol Neurosur and Ps 2004; 75: 669-76.
28. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
29. Delforge J, Mesangeau D, Dolle F, et al. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. J Nucl Med 2002; 43: 215-26.
30. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-56.
31. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006; 9: 209-23.
32. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002; 16: 352-61.
33. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006; 6: 407-28.
34. Beer AJ, Grosu AL, Carlsen J, et al.[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6610-6.
35. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000; 90: 186-98.
36. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3- integrin expression. J Nucl Med 2004; 45: 1776-83.
37. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32: 344-50.
38. Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast 2009; 18 Suppl 3: S66-73.
39. Mankoff DA PL, Petra PH, Stekhova S, et al. Factors affecting the level and heterogeneity of uptake of [F-18]fluoroestradiol (FES) in patients with estrogen receptor-positive (ER) breast cancer. J Nucl Med 2002; 43 Suppl: 286-287.
40. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18Ffluoroestradiol. J Nucl Med 2008; 49: 367-74.
41. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008; 49 Suppl 2: 149S-63S.
42. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-8.
43. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga- DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-7.
44. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-18.
45. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214-21.
46. Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep 2010; 11: 180-90.
47. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med 2010; 9: 55-61.
48. Elsasser-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50: 606-11.
49. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008; 49: 2031-41.
50. Vallabhajosula S, Kuji I, Hamacher KA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90YJ591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005; 46: 634-41.
51. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled antiprostate- specific membrane antigen monoclonal antibody J591 forandrogen-independent prostate cancer. J Clin Oncol 2004; 22: 2522-31.
52. Regino CA, Wong KJ, Milenic DE, et al. Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2009; 2: 9-17.
53. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932-40.
54. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009; 52: 347-57.
55. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26: 442-9.
56. Lee JH, Yigit MV, Mazumdar D, Lu Y. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev 2010; 62: 592-605.
57. Soontornworajit B, Wang Y. Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal Bioanal Chem 2011; 399: 1591-9.
58. Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 2011; 19: 4080-90.
59. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-80.
60. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 2007; 10: 167-75.
61. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 2007; 7: 555-68.
62. Friedman M, Stahl S. Engineered affinity proteins for tumourtargeting applications. Biotechnol Appl Biochem 2009; 53: 1-29.
63. Engfeldt T, Renberg B, Brumer H, Nygren PA, Karlstrom AE. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005; 6: 1043-50.
64. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008; 14: 2983-98.
65. Lin M, Shon IH, Lin P. Positron emission tomography: current status and future challenges. Intern Med J 2010; 40: 19-29.
66. Yap KK, Yap KS, Byrne AJ, et al. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for preoperative staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1033-40.
67. Yap JT, Carney JPJ, Hall NC, Townsend DW. Image-guided cancer therapy using PET/CT. Cancer J 2004; 10: 221-233.
68. Schinagl DA, Hoffmann AL, Vogel WV, et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer? Radiother Oncol 2009; 91: 95-100.
69. Fabi A, Di Benedetto A, Metro G, et al. HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clin Cancer Res 2011; 17: 2055-2064.
70. Pectasides D, Gaglia A, Arapantoni-Dadioti P, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumabbased therapy. Anti-cancer Res 2006; 26: 647-53.
71. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009; 15: 1848-52.
72. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008; 8: 38-49.
73. Sanchez-Munoz A, Perez-Ruiz E, Jimenez B, et al. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009; 11: 643-50.
74. Brufsky A. Trastuzumab-based therapy for patients with HER2- positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol; 33: 186-95.
75. Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 2009; 18: 22-9.
76. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010; 28: 117-9.
77. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010; 23 Suppl 2: S52-9.
78. Phillips KA, Marshall DA, Haas JS, et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009; 115: 5166-74.
79. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-79.
80. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-87.
81. antinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004.
82. Krawczyk N, Banys M, Neubauer H, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anti-cancer Res 2009; 29: 4019-24.
83. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 2007; 19: 552-7.
84. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50: 974-81.
85. Oude Munnink TH, Korte MA, Nagengast WB, et al. (89)Zrtrastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2009; 46: 678-84.
86. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2- positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586-92.
87. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
88. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res 2011; 17: 1509-20.
89. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010; 398: 232-47.
90. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-2680.
91. Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50: 417-25.
92. Cheng Z, De Jesus OP, Kramer DJ, et al. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2009; 12: 316-24.
93. Kiesewetter DO, Kramer-Marek G, Ma Y, Capala J. Radiolabelling of Her2 specyfic affibody molecule with F-18. J Fluorine Chem 2008, 129: 799-806.
94. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35: 1008-18.
95. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009; 50: 1131-9.
96. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J. 68Ga-radiolabeled DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011.
97. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A HER2- binding affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010; 37: 1356-67.
98. Ren G, Zhang R, Liu Z, et al. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 2009; 50: 1492-9.
99. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2- expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010; 51: 892-7.
100. Lawrence YR, Dicker AP. Hypoxia in prostate cancer: observation to intervention. Lancet Oncol 2008; 9: 308-9.
101. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-41.
102. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005; 46: 106-13.
103. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, Hicks RJ. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. J Pharm Pharm Sci 2007; 10: 203-11.
104. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-11.
105. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for qualified biomarker: functional assessment of treatment response in oncology. J Nucl Med 2006; 47: 901-3.
106. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
107. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009; 53: 158-66.
108. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 1992; 19: 227-37.
109. Ishiwata K, Kubota K, Murakami M, Kubota R, Senda M. A comparative study on protein incorporation of L-[methyl- 3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993; 20: 895-9.
110. Langen KJ, Borner AR, Muller-Mattheis V, et al. Uptake of cis-4- [18F]fluoro-L-proline in urologic tumors. J Nucl Med 2001; 42: 752-4.
111. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43: 153-67.
112. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Biol 2004; 31: 859-865.
113. Kenny LM, Aboagye EO, Price PM. Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol) 2004; 16: 176-85.
114. Schiepers C, Dahlbom M, Chen W, et al. Kinetics of 3'-deoxy-3'- 18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010; 51: 720-7.
115. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy- 3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34: 1339-47.
116. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010; 51: 866-74.
117. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
118. Juweid ME, Cheson BD. Current concepts - Positron-emission tomography and assessment of cancer therapy. New Engl J Med 2006; 354: 496-507.
119. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2- deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26: 1363-1378.
120. Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol 2011; 8: 517-527.
121. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005; 46: 424-8.
122. Teo BK, Seo Y, Bacharach SL, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med 2007; 48: 802-10.
123. Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007; 34: 392-404.